Chemical name: (6R-trans)-6-(1,3-benzodioxol-5-yl)- 2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino [1′, 2′
Formula: C22H19N3O4
Anabolic activity index: not a steroid
Androgenic activity index: not a steroid
MEGALIS-20
Introduction: MEGALIS-20 is a medication formulated to treat erectile dysfunction (ED) and benign prostatic hyperplasia (BPH). Manufactured by Macleods Pharmaceuticals, it contains Tadalafil, a potent phosphodiesterase type 5 (PDE5) inhibitor known for its efficacy in managing male sexual function disorders. Each pack of MEGALIS-20 includes 4 pills, with each pill containing 20 mg of Tadalafil.
Mechanism of Action: Tadalafil, the active ingredient in MEGALIS-20, works by inhibiting the enzyme PDE5, which regulates blood flow to the penis. By inhibiting PDE5, Tadalafil enhances the effects of nitric oxide, a chemical that relaxes smooth muscles in the penis during sexual stimulation. This relaxation allows increased blood flow, enabling a man to achieve and maintain an erection sufficient for sexual activity.
Indications: MEGALIS-20 is primarily indicated for the treatment of erectile dysfunction, a condition characterized by the inability to achieve or maintain an erection during sexual intercourse. Additionally, it is also used in the management of benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate gland that can cause urinary symptoms.
Dosage and Administration: Each MEGALIS-20 tablet contains 20 mg of Tadalafil. The recommended starting dose is one 20 mg tablet taken orally with a full glass of water, approximately 30 minutes to 1 hour before sexual activity. The tablet should be swallowed whole and can be taken with or without food. Avoid taking more than one tablet within a 24-hour period. For those using it for BPH treatment, the recommended dose is 5 mg once daily.
Contraindications: MEGALIS-20 is contraindicated in individuals with known hypersensitivity to Tadalafil or any inactive ingredient present in the formulation. It should not be used concurrently with nitrates or nitric oxide donors due to the risk of severe hypotension. Use of Tadalafil with alpha-blockers or antihypertensives requires careful monitoring and adjustment of dosages.
Adverse Reactions: Common adverse reactions associated with the use of MEGALIS-20 include headache, dyspepsia, back pain, myalgia, nasal congestion, flushing, and dizziness. These side effects are usually mild to moderate in severity and often transient. Serious adverse effects such as prolonged erections (priapism) and sudden loss of vision or hearing require immediate medical attention.
Precautions: Before using MEGALIS-20, patients should inform their healthcare provider of any medical conditions, especially cardiovascular disorders, liver or kidney impairment, and bleeding disorders. Caution is advised when engaging in activities requiring mental alertness, such as driving or operating machinery, until the individual’s response to Tadalafil is established.
Storage: Store MEGALIS-20 tablets at room temperature (20-25°C) in a dry place away from direct sunlight and moisture. Keep out of reach of children and pets.
Conclusion: MEGALIS-20 by Macleods Pharmaceuticals is a reliable treatment option for men suffering from erectile dysfunction and benign prostatic hyperplasia. With its active ingredient Tadalafil, it provides effective management of sexual function disorders, offering patients a renewed ability to achieve satisfactory sexual performance and improved quality of life.
This detailed product description aims to provide comprehensive information about MEGALIS-20, addressing its mechanism of action, indications, dosage, contraindications, adverse reactions, precautions, and storage requirements. For further details, consult a healthcare professional.
Reviews
There are no reviews yet.